EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The crossroads of inflammation and nutrition: predicting neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma patients

Guisheng Zhang, Bingxin Gong, Yusheng Guo, Jie Lou, Ying Peng, Siqian Cai, Zhichao Fu, Yuanji Xu, Lian Yang

Frontiers in Immunology · 2025

DOI: 10.3389/fimmu.2025.1663268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Guisheng Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Inflammation, Nutritional Status. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant immunochemotherapy (nICT) improves outcomes in esophageal squamous cell carcinoma (ESCC); however, patient response heterogeneity limits its clinical benefit. The aim of this study was to investigate the predictive value of the systemic immune-inflammation index and prognostic nutritional index score (SII-PNI score), which is jointly constructed from the systemic immune-inflammation index (SII) and prognostic nutritional index (PNI), for pathological complete response (pCR) and survival outcomes.

Methods

This retrospective study included patients with stage II to IV ESCC who received nICT therapy at Wuhan Union Hospital (WHUH), Fujian Cancer Hospital (FJCH), and 900th Hospital of the Joint Service Support Force of the People’s Liberation Army of China (900th Hospital). The predictive performance of SII-PNI score was validated using receiver operating characteristic (ROC) curves. Multivariate logistic regression confirmed SII-PNI score as an independent predictor of pCR. Additionally, Cox regression model and Kaplan-Meier survival curves were employed to analyze disease-free Survival (DFS) and overall survival (OS).

Results

A total of 345 patients were included, stratified into 0-score (n = 70), 1-score (n = 149), and 2-score (n = 126) groups. The combined cohort (Combined from FJCH cohort, WHUH cohort, 900th Hospital cohort) area under the ROC curve (AUC) revealed that SII-PNI score (AUC = 0.803) outperformed SII (AUC = 0.679, DeLong’s test P < 0.001) and PNI (AUC = 0.667, DeLong’s test P < 0.001) in predicting pCR. Compared with 0-score patients, those with 1-score (odds ratio [OR] = 0.159, 95% confidence interval [CI]:0.080-0.319, P < 0.001) and 2-score (OR = 0.025, 95% CI:0.009-0.073, P < 0.001) had significantly lower pCR rates. The 2-score group showed had shorter of DFS (hazard ratio [HR] = 2.487, 95% CI:1.414-4.374, P = 0.002) and OS (HR = 4.473, 95% CI:2.138-9.357, P < 0.001) versus the 0-score group.

Conclusions

This study demonstrated for the first time that the SII-PNI score can be used as an independent predictor of pCR in patients with ESCC treated with nICT and has prognostic stratification value. This suggests that it has the potential to be a pre-treatment assessment tool for evaluating treatment response and prognosis before nICT treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaEsophageal NeoplasmsInflammationNutritional StatusHumansMaleFemaleMiddle AgedNeoadjuvant TherapyRetrospective StudiesAgedPrognosisTreatment OutcomeNutrition AssessmentImmunotherapyAdultNeoplasm Staging

Stichwörter der Autor:innen

esophageal squamous cell carcinomaimmunochemotherapyneoadjuvantpathological complete responseprognostic nutritional indexsystemic immune-inflammation index

Autor:innen und Institutionen

  • Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Provincial Clinical Research Center for Precision Radiology and Interventional Medicine, Wuhan, China.
  • Hubei Key Laboratory of Molecular Imaging, Wuhan, China.
  • College of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, China.
  • Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Department of Radiotherapy, Fuzong Clinical Medical College (900th Hospital), Fujian Medical University, Fuzhou, Fujian, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, G., Gong, B., Guo, Y., Lou, J., Peng, Y., Cai, S., Fu, Z., Xu, Y., & Yang, L. (2025). The crossroads of inflammation and nutrition: predicting neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma patients. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1663268

Vancouver

Zhang G, Gong B, Guo Y, Lou J, Peng Y, Cai S, et al. The crossroads of inflammation and nutrition: predicting neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma patients. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1663268

BibTeX
@article{Zhang2025,
  author = {Zhang, Guisheng and Gong, Bingxin and Guo, Yusheng and Lou, Jie and Peng, Ying and Cai, Siqian and Fu, Zhichao and Xu, Yuanji and Yang, Lian},
  title = {The crossroads of inflammation and nutrition: predicting neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma patients},
  journal = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1663268}
}
Kostenlos starten →